Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
- Conditions
- ObesityDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06937203
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT06880770
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 840
- Registration Number
- NCT06822790
Treatment Protocol of Plozasiran in Adults With FCS
- Conditions
- Familial Chylomicronemia
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Registration Number
- NCT06796426
- Locations
- 🇺🇸
Arrowhead Pharmaceuticals, Inc., Pasadena, California, United States
Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT06700538
- Locations
- 🇳🇿
Research Site, Grafton, Auckland, New Zealand
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
- Conditions
- Spinocerebellar Ataxia Type 2
- Interventions
- Drug: ARO-ATXN2 InjectionDrug: Placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06672445
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
🇨🇦Research Site 2, Montréal, Quebec, Canada
🇨🇦Research Site 1, Montréal, Quebec, Canada
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 1328
- Registration Number
- NCT06347133
- Locations
- 🇺🇸
University of Louisville Research Foundation, Louisville, Kentucky, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06347016
- Locations
- 🇺🇸
Ascension St. Vincents Birmingham, Birmingham, Alabama, United States
🇺🇸IMC-Diagnostic and Medical Clinic LLC, Mobile, Alabama, United States
🇺🇸National Heart Institute, Beverly Hills, California, United States
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 405
- Registration Number
- NCT06347003
- Locations
- 🇺🇸
Andres Garcia Zuniga MD PA, Laredo, Texas, United States
🇧🇪De Meulemeester, Marc, Gozée, Belgium
🇧🇪Jesse Ziekenhuis, Hasselt, Belgium
Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT06209177
- Locations
- 🇳🇿
New Zealand Clinical Research OPCO Ltd, Auckland, New Zealand